REGENXBIO Inc. (RGNX) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

9/25

Growth 2 Margin 1 Expansion 3 Platform 1 Financial 2

latest quarter score

Earnings Reports

9
Regenxbio (RGNX) Q2 2026: $310M Cash Infusion Extends Runway, Accelerates RGX202 Launch Path
August 06, 2026
11
InMode (INMD) Q1 2026: North America Drives 5% Growth as Gross Margin Narrows to 75%
May 14, 2026
10
Regenxbio (RGNX) Q4 2025: $100M Milestone Unlock Signals Commercial Readiness Amid Pipeline Catalysts
March 05, 2026
10
Regenexx Bio (RGNX) Q3 2025: RGX202 Pivotal Trial Enrollment Completes Early, Accelerating Path to 2026 Filing
November 06, 2025
10
RegeneX Bio (RGNX) Q2 2025: $100M Milestone Fuels Dual Pivotal Launches in Gene Therapy Pipeline
August 07, 2025
9
RegenxBio (RGNX) Q1 2025: $110M Upfront Fuels Pipeline as RGX202 Trial Surpasses 50% Enrollment
July 07, 2025
11
REGENXBIO (RGNX) Q4 2024: BLA Submission and Rapid Duchenne Trial Enrollment Signal Pipeline Acceleration
March 13, 2025

Browse all companies